Oral targeted drug shows encouraging activity in patients with relapsed or resistant AML

An oral targeted drug has shown encouraging activity and tolerable side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia - a poor-prognosis group with few options - report investigators from Dana-Farber Cancer Institute and M.D. Anderson Cancer Center. Of 32 patients treated with the oral inhibitor ABT-199, five had eradication of their leukemia and several more had stable disease, according to Anthony Letai, MD, PhD, of Dana-Farber, senior author of the report.

http://ift.tt/1wnHrJd